ORION INFUSION LIMITED

CONDENSED INTERIM FINANCIAL STATEMENTS (UN-AUDITED)
AS AT AND FOR PERIOD ENDED MARCH 31, 2025
(THIRD QUARTER)

ORION INFUSION LIMITED
CONDENSED STATEMENT OF FINANCIAL POSITION (UN-AUDITED)
AS AT MARCH 31, 2025

Particulars	Notes	Amount in Taka	
		31-Mar-25	30-Jun-24
ASSETS			
Non-Current Assets:		**384,252,254**	**386,866,502**
Property, Plant & Equipment	05.00	346,472,591	352,385,481
Right-of-use Assets	06.00	13,645,609	11,764,172
Investments	07.00	24,134,054	22,716,849
Current Assets:		**475,373,330**	**437,876,717**
Inventories	08.00	158,535,846	139,509,706
Trade and other Receivables	09.00	121,700,645	124,829,387
Advances, Deposits & Prepayments	10.00	171,450,032	151,196,022
Cash and Cash Equivalents	11.00	23,686,806	22,341,602
TOTAL ASSETS		**859,625,584**	**824,743,219**
SHAREHOLDERS' EQUITY AND LIABILITIES			
Shareholders' Equity:		**319,928,541**	**314,623,659**
Share Capital	12.00	203,597,600	203,597,600
Retained Earnings		(18,854,840)	(24,044,910)
Reserves	13.00	135,185,781	135,070,969
Non-Current Liabilities:		**28,522,444**	**26,609,667**
Lease Obligation	14.00	8,711,805	7,023,900
Deferred Tax Liabilities	15.00	19,810,639	19,585,767
Current Liabilities:		**511,174,598**	**483,509,893**
Current Portion of Lease Obligation	14.01	6,286,528	6,160,348
Short Term Loans	16.00	302,209,693	305,152,114
Trade and Other Payables	17.00	56,228,823	53,204,533
Accrued Expenses	18.00	97,572,612	94,202,349
Unclaimed/Unpaid Dividend		48,876,943	24,790,549
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**859,625,584**	**824,743,219**
Net Asset Value (NAV) Per Share of Tk. 10 Each		**15.71**	**15.45**
Number of Shares used to compute NAV		**20,359,760**	**20,359,760**

Sd/-	**Sd/-**	**Sd/-**	**Sd/-**	**Sd/-**
Chairman	**Managing Director**	**Director**	**Chief Financial Officer**	**Company Secretary**

ORION INFUSION LIMITED

CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UN-AUDITED)
FOR THE PERIOD ENDED MARCH 31, 2025 (THIRD QUARTER)

Particulars	Note	Amount in Taka			
		July 2024 to March 2025	July 2023 to March 2024	January to March 2025	January to March 2024
Revenue	19	**495,180,323**	**647,512,253**	**101,490,544**	**208,925,860**
Cost of Goods Sold		(287,678,432)	(390,126,228)	(55,111,891)	(124,920,748)
Gross Profit		**207,501,891**	**257,386,026**	**46,378,653**	**84,005,112**
Operating Expenses		**(143,467,442)**	**(192,993,699)**	**(30,206,249)**	**(65,142,507)**
Administrative Expenses		(21,542,765)	(29,850,770)	(4,386,358)	(10,104,363)
Selling & Distribution Expenses		(121,924,677)	(163,142,930)	(25,819,891)	(55,038,144)
Profit from Operation		**64,034,449**	**64,392,326**	**16,172,404**	**18,862,606**
Financial Expenses	20	(27,215,229)	(24,247,562)	(6,824,055)	(8,042,899)
Non Operating Income / (Loss)	21	1,129,768	646,775	655,337	80,992
Net Profit from Operation		**37,948,988**	**40,791,539**	**10,003,686**	**10,900,699**
Workers' Profit Participation Fund		(1,807,095)	(1,942,454)	(476,366)	(519,081)
Net Profit Before Tax		**36,141,894**	**38,849,085**	**9,527,320**	**10,381,618**
Income Tax expense	22	**(7,686,535)**	**(9,284,366)**	**(2,039,707)**	**(2,515,277)**
Current Tax	22.01	(7,228,379)	(8,736,501)	(1,905,464)	(2,335,864)
Deferred Tax Income/(Expenses)		(458,156)	(547,865)	(134,243)	(179,413)
Net Profit After Tax		**28,455,358**	**29,564,719**	**7,487,613**	**7,866,341**
Add: Other Comprehensive Income		**1,443,452**	**2,041,160**	**665,538**	**(68,271)**
Fair Value Adjustment of Marketable Securities		1,210,168	(598,640)	587,776	(129,662)
Deferred Tax Income/(Expense) on Revaluation Surplus on PPE		233,285	2,639,800	77,762	61,391
Total Comprehensive Income		**29,898,810**	**31,605,878**	**8,153,151**	**7,798,070**
Earning Per Share	23	**1.40**	**1.45**	**0.37**	**0.39**

Sd/-	Sd/-	Sd/-	Sd/-	Sd/-
Chairman	**Managing Director**	**Director**	**Chief Financial Officer**	**Company Secretary**

ORION INFUSION LIMITED

CONDENSED STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)

FOR THE PERIOD ENDED MARCH 31, 2025 (THIRD QUARTER)

Amount in Taka

Particulars	Ordinary Share Capital	Retained Earnings	Reserves	Total
Balance at July 01, 2024	**203,597,600**	**(24,044,910)**	**135,070,969**	**314,623,660**
Net Profit during the Period	-	28,455,358	-	**28,455,358**
Cash Dividend for the year 2023-2024		(24,431,712)		**(24,431,712)**
Fair value adjustment for sell of marketable securities	-	-	(162,217)	**(162,217)**
Transfer between Reserve & Retained earnings for depreciation on Revaluation surplus.	-	1,166,423	(1,166,423)	-
Fair Value Gain/(Loss) on Marketable Securities	-	-	1,210,168	**1,210,168**
Adjustment for deferred tax on Revaluation Surplus	-	-	233,285	**233,285**
Balance at March 31, 2025	**203,597,600**	**(18,854,840)**	**135,185,781**	**319,928,541**

FOR THE PERIOD ENDED MARCH 31, 2024 (Third Quarter)

Amount in Taka

Particulars	Ordinary Share Capital	Retained Earnings	Reserves	Total
Balance at July 01, 2023	**203,597,600**	**(48,438,652)**	**136,493,515**	**291,652,462**
Net Profit during the Period	-	29,564,719	-	**29,564,719**
Cash Dividend for the year (2022-2023)	-	(20,359,760)		**(20,359,760)**
Fair value adjustment for sell of marketable securities	-	-	33,995	**33,995**
Transfer between Reserve & Retained earnings for depreciation on Revaluation surplus.	-	1,227,814	(1,227,814)	-
Fair Value Gain/(Loss) on Marketable Securities	-	-	(598,640)	**(598,640)**
Adjustment for Right-of-use Assets	-	782,993		**782,993**
Adjustment for deferred tax on Revaluation Surplus	-	-	2,639,800	**2,639,800**
Balance at March 31, 2024	**203,597,600**	**(37,222,887)**	**137,340,855**	**303,715,568**

Sd/- **Sd/-** **Sd/-** **Sd/-** **Sd/-**
Chairman **Managing Director** **Director** **Chief Financial Officer** **Company Secretary**

ORION INFUSION LIMITED

CONDENSED STATEMENT OF CASH FLOWS (UN-AUDITED)

FOR THE PERIOD ENDED MARCH 31, 2025 (THIRD QUARTER)

Particulars	Note	Amount in Taka	
		July 2024 to March 2025	July 2023 to March 2024
Cash Flows from Operating Activities :			
Receipts :			
Cash received from Customers		498,309,065	677,144,827
Other Income / (Loss)		1,129,768	646,775
		499,438,833	**677,791,601**
Payments :			
Cash paid to Suppliers		(293,663,743)	(374,447,963)
Cash paid for operating Expenses		(146,883,418)	(189,780,985)
Cash paid for Financial Expenses		(27,215,229)	(24,247,562)
Income Tax paid and Deducted at Source		(16,402,956)	(19,055,056)
		(484,165,346)	**(607,531,567)**
Net Cash Received / (Used) from Operating Activities		**15,273,487**	**70,260,035**
Cash Flows from Investing Activities :			
Acquisition of Property, Plant & Equipments		(5,058,957)	(15,717,108)
Received from / (Payment to) Securities & Others		(369,255)	(10,103)
Net Cash Received / (Used) from Investing Activities		**(5,428,212)**	**(15,727,211)**
Cash Flows from Financing Activities :			
Increase/ (Decrease) in Liabilities for Other Finance		(5,212,331)	(7,205,685)
Dividend Paid		(345,318)	(10,953,223)
Bank Loans Received / (Repaid)		(2,942,421)	(62,121,872)
Net Cash Received / (Used) from Financing Activities		**(8,500,071)**	**(80,280,780)**
Net Increase /(Decrease) in Cash & Cash Equivalents		**1,345,205**	**(25,747,956)**
Cash & Cash Equivalents at the beginning of the period		22,341,602	44,991,235
Cash & Cash Equivalents at the End of the Period		**23,686,806**	**19,243,279**
Net Operating Cash Flow Per Share	**26**	**0.75**	**3.45**
Number of Shares used to compute NOCFPS		**20,359,760**	**20,359,760**

Sd/-	**Sd/-**	**Sd/-**	**Sd/-**	**Sd/-**
Chairman	**Managing Director**	**Director**	**Chief Financial Officer**	**Company Secretary**

ORION INFUSION LIMITED
Notes, comprising a summary of significant accounting policies and other explanatory information
As at and for the period ended March 31, 2025

01.00 Reporting Entity

01.01 Background of the Entity

Orion Infusion Limited is a public limited company incorporated in Bangladesh on 05 May 1983 and is now operating under the banner of Orion Group. The Company was converted into a public limited company on 05 October 1994. The registered office of the company "Orion House" is situated at 153-154 Tejgaon Industrial Area, Dhaka-1208, Bangladesh. Production plant of the company is situated at Maikuli, P.S.-Rupganj, and District- Naraynganj, Bangladesh.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996.

01.02 Nature of Business

Orion Infusion Limited is devoted in producing Large Volume Parenteral (LVP) & other lifesaving injectable products. The company has the manufacturing facilities for the production of I.V. Rehydration Solutions, Electrolyte Solutions, and Solution for Acidosis, Ranitidine I.V. infusion, Anti-Microbial products viz. Ciprofloxacin I.V., Metronidazole I.V. etc. To meet the tremendous increment of the demand of its products, Orion Infusion Ltd. is now set to expand its production capacity further by installing modern and sophisticated technologies which will certainly rich its core competence. The company is now producing pure steam generated fluids, required by GMP instead of Black steam generated fluids. Innovative product like Amino acids solution was introduced by Orion Infusion Ltd., which was the first ever manufactured in Bangladesh and this has given Orion Infusion Ltd. a competitive advantage over others. Orion Infusion Ltd. Quality Manual describes the quality policies & company wide control structure of the quality management system (QMS), which is leading towards achieving its corporate vision and mission.

02.00 Basis of Preparation and Presentation of Financial Statements

02.01 Statement of Compliance

The financial statements have been prepared in accordance with International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), the Companies Act 1994, Securities and Exchange Rules 1987 and other relevant local laws as applicable.

02.02 Components of the Condensed Financial Statements

According to IAS-34 " Interim Financial Reporting,", these interim financial statements include the following components-

i. Condensed Statement of Financial Position
ii. Condensed Statement of Profit or Loss and other Comprehensive Income
iii. Condensed Statement of Changes in Equity
iv. Condensed Statement of Cash Flows
v. Selected Explanatory Notes to the Condensed Financial Statements

02.03 Basis of Measurement

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value as explained in the accompanying notes.

02.04 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Taka/Tk./BDT, which is the company's functional currency. The Company earns its major revenues in BDT and all other incomes/expenses and transactions are in BDT.

02.05 Comparative Information

Comparative information has been disclosed in respect of the year or period for all numerical information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year's financial statements.

Comparative figures have been re-arranged where considered necessary to ensure better comparability with the current period without causing any impact on the profit and value of assets and liabilities as reported in the financial statements.

02.06 Reporting Period

The Financial period of the company covers from July 01, 2024 to March 31, 2025.

02.07 Use of Estimates and Judgments

The preparation of financial statements in conformity with International Financial Reporting Standards requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected as required by IAS 8: "Accounting Policies, Changes in Accounting Estimates and Errors".

02.08 Materiality, Aggregation and Off setting

Each material item as considered by management significant has been displayed separately in the financial statements. No amount has been set off unless the company has legal right to set off the amounts and intends to settle on net basis. Income and expenses are presented on a net basis only when permitted by the relevant accounting standards. The values of any asset or liability as shown in the statement of financial position are not off-set by way of deduction from another liability or asset unless there exist a legal right therefore. No such incident existed during the year.

02.09 Going Concern Review

As per IAS-1, a company is required to make assessment at the end of each year to make assessment of its capability to continue as going concern. Management of the company makes such assessment each year. The company has adequate resources to continue its operation for the foreseeable future and has wide coverage of its liabilities. For this reason, the directors continue to adopt going concern assumption while preparing the financial statements.

02.10 Date of Authorization

The financial statements were authorized for issue by the Board of Directors in its meeting held on **April 29, 2025** for publication.

03.00 Accounting Policies and Methods of Computations

IFRS-16: Leases

In January 2016, the International Accounting Standards Board (IASB) issued IFRS-16 which is effective from annual reporting period beginning on or after 1 January 2019. The company has applied IFRS-16 Leases for the first time with the date of initial application of 01 July 2019.

IFRS 16 introduces new or amended requirements with respect to lease accounting. It introduces significant changes to lessee accounting by removing the distinction between operating and finance lease and requiring the recognition of a right-of-use asset and a lease liability at commencement for all leases.
The Company has applied IFRS 16 using the modified retrospective approach and therefore the comparative information has not been restated.

04.00 Subsequent Events

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

Note	Particulars		Amount in Taka	
			31-Mar-25	30-Jun-24
05.00	**Property, Plant and Equipment**			
	A) At Historical Cost			
	Opening Balance (At Cost)		659,561,953	648,147,365
	Add: Addition during the Period		5,058,957	11,414,588
	Less : Disposal during the Period		-	-
			664,620,910	**659,561,953**
	Opening Balance of Depreciation		456,303,041	442,574,946
	Charged during the Period		9,805,425	13,728,095
	Less : Disposal during the Period		-	-
	Accumulated depreciation		**466,108,465**	**456,303,041**
	Written down value		**198,512,445**	**203,258,913**
	B) At Revaluation			
	Opening Balance		166,981,322	166,981,322
			166,981,322	**166,981,322**
	Less: Depreciation			
	Opening Balance of Depreciation		17,854,753	16,217,668
	Charged during the Period		1,166,423	1,637,085
	Accumulated depreciation		**19,021,176**	**17,854,753**
	Written down value		**147,960,146**	**149,126,569**
	Total Carrying Value (A+B)		**346,472,591**	**352,385,481**
06.00	**Right-of-use Assets**			
	A) At Historical Cost			
	Opening Balance (At Cost)		57,195,190	58,744,047
	Add: Addition during the Period		7,026,416	2,032,485
			64,221,606	**60,776,532**
	Less: Disposal/ Adjustment		-	(3,581,342)
			64,221,606	**57,195,190**
	Opening Balance of Depreciation		45,431,018	37,518,846
	Charged during the Period		5,144,979	7,912,172
	Accumulated depreciation		**50,575,997**	**45,431,018**
	Written down value		**13,645,609**	**11,764,172**
07.00	**Investments**			
	Investment in Non-quoted Shares	**Note - 07.01**	16,825,396	16,825,396
	Investment in Marketable Securities	**Note - 07.02**	6,924,275	5,519,170
	Fixed Deposit (FDR), Agrani Bank, WASA Branch		384,383	372,283
			24,134,054	**22,716,849**

07.01 Investment in Non-quoted Shares

ICB Islamic Bank Ltd.	16,825,396	16,825,396
	16,825,396	**16,825,396**

07.02 Investment in Marketable Securities

	31-Mar-25		30-Jun-24	
A. Southeast Bank Capital Services Ltd.	**Market Price**	**Cost Price**	**Market Price**	**Cost Price**
Islami Bank Bangladesh Ltd.	-	-	3,260,000	4,528,494
Aftab Automobiles Ltd.	1,665,000	1,853,810	-	-
Sandhani Life Insurance Co. Ltd.	652,700	1,297,726	744,200	1,297,726
Monno Ceramics Ltd.	3,045,600	3,031,839	-	-
Associated Oxygen Limited	96,000	234,217	106,200	234,217
	5,459,300	**6,417,592**	**4,110,400**	**6,060,437**
B. Bank Asia Securities Ltd.				
Premier Leasing & Finance	77,175	387,418	74,970	387,419
Eastern Housing Limited	1,387,800	2,263,745	1,333,800	2,263,745
	1,464,975	**2,651,163**	**1,408,770**	**2,651,163**
	6,924,275	**9,068,755**	**5,519,170**	**8,711,601**

08.00 Inventories

Raw Materials	44,263,109	46,249,534
Packing Materials	38,881,328	45,915,293
Work - in - process	2,575,878	7,558,052
Finished Goods	10,165,671	16,246,470
Promotional Materials	4,990,893	4,662,607
Printing & Stationeries	4,511,792	4,692,280
Goods in Transit	53,147,176	14,185,470
	158,535,846	**139,509,706**

09.00 Trade and other receivables

Accounts Receivables	121,700,645	124,829,387
	121,700,645	**124,829,387**

This is unsecured, considered good and is falling due within one year. Classification schedule as required by schedule XI of Companies Act 1994 are as follows:

Aging of the above balance is as follows:

Below 180 days	121,700,645	124,829,387
Above 180 days	-	-
	121,700,645	**124,829,387**

Particulars	Amount in Taka	
	31-Mar-25	30-Jun-24
I. Accounts Receivable considered good in respect of which the company is fully secured	121,700,645	124,829,387
II. Accounts Receivable considered good in respect of which the company holds no security other than the debtor personal security	-	-
III. Accounts Receivable considered doubtful or bad	-	-
IV. Accounts Receivable due by any director or other officer of the company	-	-
V. Accounts Receivable due by Common Management	-	-
VI. The maximum amount of receivable due by any director or other officer of the company	-	-
Total	**121,700,645**	**124,829,387**

As at March 31, 2025 the company did not make any provision against trade receivables as there as no indication of impairment.

10.00 Advances, Deposits & Prepayments

Advances			
Advance Income Tax	**Note - 10.01**	136,294,626	119,891,670
Travel and Other Advances		228,655	576,048
Advance paid to Suppliers		564,377	224,228
Advance for Office Rent		1,049,372	873,599
Motor Cycle & Car Advance		107,446	242,458
Advance against C&F		19,847,891	13,477,816
Advance Against Cash Purchase		-	303,027
		158,092,366	**135,588,846**
Deposits			
Security Deposit		6,393,328	6,416,651
Bank Guarantee		3,376,793	3,376,793
Earnest Money		754,840	654,840
Collection & Other Advance		2,197,645	1,523,058
L/C Margin & Balance		635,060	3,635,834
		13,357,665	**15,607,176**
		171,450,032	**151,196,022**

10.01 Advance Income Tax

Opening Balance	119,891,670	96,833,116
Income tax paid and TDS during the period	16,402,956	23,058,554
	136,294,626	**119,891,670**

11.00 Cash and Cash Equivalents

Cash in Hand	**4,582,109**	**1,316,734**
(a) Cash in Hand/Imprest Cash	4,380,345	1,046,512
(b) Balance at Brokerage House	201,764	270,222
(c) Cash at Bank	**19,104,698**	**21,024,868**
Current Account (Main)	16,628,371	13,762,181
Current Account (Collection)	1,019,065	2,605,414
Short Term Deposit Account	1,457,263	4,657,273
Total	**23,686,806**	**22,341,602**

Note	Particulars	Amount in Taka	
		31-Mar-25	30-Jun-24

12.00 Share Capital

a) Authorized Capital

100,000,000 Ordinary Shares of Taka 10/- each	**1,000,000,000**	**1,000,000,000**

b) Issued, Subscribed and Paid-up Capital

20,359,760 Ordinary Shares of Taka 10/- each	**203,597,600**	**203,597,600**

c) Distribution Schedule

The detailed schedule showing the number of shareholders and their shareholding in percentage has been disclosed below as a requirement of the Regulation 37(3) of Dhaka Stock Exchange and Chittagong Stock Exchange.

Range of holding in number of shares	No. of Shareholders	Number of Shares held	Percentage of Shareholding 31.03.2025	Percentage of Shareholding 30.06.2024
Up to 500 shares	4,906	804,077	3.95%	4.39%
501 to 5,000 shares	1,666	2,524,745	12.40%	13.19%
5,001 to 10,000 shares	147	1,034,396	5.08%	4.38%
10,001 to 20,000 shares	80	1,148,588	5.64%	3.44%
20,001 to above	70	14,847,954	72.93%	74.59%
Total	**6,869**	**20,359,760**	**100%**	**100%**

d) Shareholding Position as on March 31, 2025 is as follows:

Composition of Shareholding	No. of Shareholders	Number of Shares held	Percentage of Shareholding 31 March 2025	Percentage of Shareholding 30 June 2024
Sponsors	4	8,268,400	40.61%	40.61%
Foreign Investors	27	9,960	0.05%	0.05%
Institutional	241	3,094,295	15.20%	5.17%
General Public	6,597	8,987,105	44.14%	54.16%
Total	**6,869**	**20,359,760**	**100%**	**100%**

13.00 Reserves

Revaluation surplus on PPE	**Note: 13.01**	137,330,262	138,263,400
Fair value changes in investment	**Note: 13.02**	(2,144,480)	(3,192,431)
		135,185,781	**135,070,969**

13.01 Revaluation surplus on Property, plant and equipment

Opening Balance	138,263,400	138,754,526
Depreciation on revalued asset	(1,166,423)	(1,637,085)
Adjustment for deferred tax on Revaluation Surplus	233,285	1,145,959
	137,330,262	**138,263,400**

Note	Particulars		Amount in Taka	
			31-Mar-25	30-Jun-24
13.02	**Fair value changes in investment**			
	Opening Balance		(3,192,431)	(2,261,011)
	Fair Value adjustment for sale of Securities		(162,217)	44,494
	Fair Value Gain/(Loss) on Marketable Securities		1,210,168	(975,914)
			(2,144,480)	**(3,192,431)**
14.00	**Lease Obligation**			
	Lease Obligation (Office Rent)		14,998,333	13,184,248
			14,998,333	**13,184,248**
	Current portion of lease obligation	**Note: 14.01**	(6,286,528)	(6,160,348)
			8,711,805	**7,023,900**
14.01	**Current portion of lease obligation**			
	Lease Obligation (Office Rent)		6,286,528	6,160,348
			6,286,528	**6,160,348**
15.00	**Deferred Tax Liabilities**			
	Opening Balance		19,585,767	21,725,601
	Addition/Adjustment D/P charged to Income tax expenses		458,156	(993,874)
	Adjustment with revaluation Surplus on PPE		(233,285)	(1,145,959)
			19,810,639	**19,585,767**

Deferred Tax (Income)/ Expense:

Particulars	Accounting Base	Tax Base	Deferred Tax (Assets)/ Liabilities as on 31 March 2025	Deferred Tax (Assets)/ Liabilities as on 30 June 2024
Historical Cost				
Written Down Value on PPE	200,680,007	134,875,043	13,160,993	12,558,628
Unrealized gain/(loss) on Mkt.	1,210,168	-	121,017	(97,591)
Lease Liabilities	(14,998,333)	-	(2,999,667)	(2,636,850)
Total	**186,891,842**	**134,875,043**	**10,282,343**	**9,824,187**

Closing Deferred Tax (Asset)/ Liability	10,282,343	9,824,187
Opening Deferred Tax (Asset)/ Liability	9,824,187	10,818,061
Deferred Tax (Income)/ Expense:	**458,156**	**(993,874)**

Revaluation

Land & Land Development	118,021,954	-	3,540,659	3,540,659
Building	29,938,192	-	5,987,638	6,220,923
Total	**147,960,146**	**-**	**9,528,297**	**9,761,582**

Closing Deferred Tax (Asset)/ Liability	9,528,297	9,761,582
Opening Deferred Tax (Asset)/ Liability	9,761,582	10,907,541
Deferred Tax (Income)/ Expense:	**(233,285)**	**(1,145,959)**

Note	Particulars		Amount in Taka	
			31-Mar-25	30-Jun-24
16.00	**Short Term Loans**			
	Agrani Bank C.C. (Hypothecation) - 54566, WASA Branch		206,360,942	206,382,450
	Agrani Bank (LTR), WASA Branch- 4786		95,848,751	98,769,664
			302,209,693	**305,152,114**
17.00	**Trade and other payables**			
	Trade Payables		56,228,823	53,204,533
			56,228,823	**53,204,533**
18.00	**Accrued Expenses**			
	Utilities		1,723,883	2,331,517
	Salary and Wages		13,158,447	16,185,342
	Employee Benefit Payable		9,353,954	7,546,859
	Audit Fee		-	287,500
	Corporate Governance Audit Fee		-	69,000
	Provision for Income Tax	**Note: 18.01**	71,713,639	64,485,260
	Others payable		1,622,690	3,296,871
			97,572,612	**94,202,349**
18.01	**Provision for current tax**			
	Opening Balance		64,485,260	54,886,848
	Add: Provision made during the period		7,228,379	9,769,704
	Less: Paid during the period		-	(171,292)
			71,713,639	**64,485,260**

Notes	Particulars	Amount in Taka	
		July 2024 to March 2025	July 2023 to March 2024
19.00	**Revenue**		
	Local Sales	495,180,323	647,512,253
		495,180,323	**647,512,253**
20.00	**Financial Expenses**		
	Interest on C.C. (Hypo), Agrani Bank Ltd.	16,919,681	15,700,638
	Interest on LTR Loan Agrani Bank Ltd.	9,347,177	7,492,839
	Interest on Phoenix Finance & Investment Limited	-	9,838
	Finance Cost (Lease Obligation-Office Rent)	948,371	1,044,247
		27,215,229	**24,247,562**
21.00	**Non Operating Income**		
	Other Income	759,315	470,297
	Bank Interest	22,976	16,694
	Interest on FDR	14,412	12,059
	Capital Gain/(Loss) on Marketable Securities	162,217	(33,995)
	Dividend Income	170,848	181,720
		1,129,768	**646,775**

Particulars		Taxable Income	Taxable Amount	
			31-Mar-25	31-Mar-24

22.00 Income Tax Expense

Current Tax on profit for the Period	**Note - 25.01**	7,228,379	8,736,501
Deferred tax expense/(income)		458,156	547,865
		7,686,535	**9,284,366**

Taxable profit	35,971,046	7,194,209	8,700,157
Dividend income	170,848	34,170	36,344
Total	**36,141,894**	**7,228,379**	**8,736,501**

Minimum Tax

Calculation of gross receipt

Revenue:

Sales	495,180,323	647,512,253
Other Income	953,139	668,711
Interest on FDR	14,412	12,059
Capital Gain/(Loss) on Marketable Securities	162,217	(33,995)
Total Gross Receipts	**496,310,091**	**648,159,028**
Minimum Tax (0.60% On Total Gross Receipts)	**2,977,861**	**3,888,954**

Disclosures as per BSEC NOTIFICATION No. BSEC/CMRRCD/2006-158/208/ADMIN/81 Dated 20 June, 2018

23.00 Earning Per Share (EPS)

The computation is given below

Net Profit After Tax	28,455,358	29,564,719
Ordinary shares outstanding during the Period	20,359,760	20,359,760
	1.40	**1.45**

24.00 Acquisition of Property Plant & Equipments during the period

SL. NO.	Particulars	Amount in Taka	
		31-Mar-25	30-Jun-24
1	Building	-	1,855,622
2	Plant & Machinery	2,568,426	5,620,341
3	Office Equipment	2,490,531	3,938,625
Total		**5,058,957**	**11,414,588**

Note	Particulars	Amount in Taka	
		01.07.2024 to 31.03.2025	01.07.2023 to 31.03.2024
25.00	**Reconciliation of net profit with cash flows from operating activities**		
	Net Profit before tax	**36,141,894**	**38,849,085**
	Interest & other income	(1,129,768)	(646,775)
	Financial Expenses	27,215,229	24,247,562
	(Increase) /Decrease in accounts receivables	3,128,742	29,632,573
	Increase in Inventory	(19,026,140)	1,060,951
	Increase /(Decrease) in trade payable	3,024,290	3,810,547
	Increase /(Decrease) in accrued expenses	(3,858,116)	1,244,748
	Depreciation	16,116,827	17,925,324
	Increase in Advance, Deposit & Prepayments	(3,851,054)	(3,208,137)
	Cash generated from operating activities	**57,761,903**	**112,915,879**
	Investment Income	1,129,768	646,775
	Finance Cost paid	(27,215,229)	(24,247,562)
	Income taxes paid	(16,402,956)	(19,055,056)
	Net cash flows from operating activities	**15,273,487**	**70,260,035**
26.00	**Calculation of Net operating cash flow per share (NOCFPS)**		
	Net Cash flow from operating activities	15,273,487	70,260,035
	No. of Shares	20,359,760	20,359,760
	Net operating cash flow per share (NOCFPS)	**0.75**	**3.45**

NOCFPS decreased to .75 than 3.45 of the previous corresponding period. During the period cash received from customer is decreased than the previous corresponding period.

27.00	**Calculation of Net Asset Value Per Share**	859,625,584	824,743,219
	Total Assets	539,697,042	510,119,559
	Total Liabilities	**319,928,541**	**314,623,660**
	Net Assets	20,359,760	20,359,760
	No. of Share	**15.71**	**15.45**
	Net Asset Value (NAV) Per Share		

Sd/-	Sd/-	Sd/-	Sd/-	Sd/-
Chairman	**Managing Director**	**Director**	**Chief Financial Officer**	**Company Secretary**